Details for 2022180767
Up to date per 01.04.2026
Actions
Details for 2022180767
Granted/Registered
European Patent
25.01.2023 A
10.04.2024 B1
19.12.2016
US
201662436199 P
06.01.2017
US
201762443481 P
30.03.2017
US
201762479177 P
22.09.2017
US
201762562119 P
A61K 47/64 20170101AFI20231101BHEP
Owner
Sarepta Therapeutics, Inc.215 First Street, Suite 415 Cambridge, MA 02142US
Representative
No representatives present
Inventor
PASSINI, Marco, A. Cambridge, 02142US
HANSON, Gunnar, J. Cambridge, 02142US
Information about Fees